Skip to main content

Table 3 Univariate and multivariate analysis for pathologic complete response

From: Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study

Variables ER-Positive (N = 1048) ER-Negative (N = 797)
Univariate Multivariate Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Age<35 vs. 35≤Age<50 1.17 (0.51–2.67) 0.71 0.41 (0.05–3.19) 0.39 1.92 (1.17–3.13) 0.01 2.54 (1.27–5.08) 0.01
PR-negative vs. –positive 1.87 (1.01–3.47) 0.05 2.00 (0.68–5.88) 0.21 1.60 (0.78–3.27) 0.20 5.45 (1.26–23.61) 0.02
HER2-positive vs. –negative 0.67 (0.33–1.37) 0.28 NI   1.33 (0.82–2.16) 0.25 NI  
Proliferative index: high vs. low 2.30 (1.02–5.20) 0.05 3.45 (1.17–10.15) 0.03 1.00 (0.58–1.74) 0.99 1.22 (0.60–2.46) 0.58
Nonpalpable vs. palpable 3.28 (0.93–11.54) 0.06 1.61 (0.20–13.16) 0.66 2.27 (0.93–5.53) 0.07 3.95 (1.32–11.8) 0.01
  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, CI confidence interval, NI not included in the model